Tulsi Gabbard’s Biolab Release: Transparency Breakthrough or Political Rebranding?
ODNI says it found evidence of U.S. funding for more than 120 biolabs in over 30 countries. The release is real — but the interpretation is where the fight begins.
The Office of the Director of National Intelligence has released a politically explosive statement: DNI Tulsi Gabbard says U.S. intelligence files show longstanding American funding for more than 120 biological laboratories in more than 30 countries, including facilities in Ukraine. The release is tied to President Trump’s order to end federal funding for dangerous gain-of-function research overseas and to expand transparency around what pathogens these labs contain.
That part is real. The official ODNI statement says the Intelligence Community found evidence of U.S. government funding for more than 120 foreign biolabs and warned that at least one U.S.-funded lab in Ukraine likely housed dangerous pathogens while being vulnerable to attack or seizure during the Russia-Ukraine war. It also says some facilities have conducted work involving hazardous pathogens, including in some cases gain-of-function research.
But the political meaning is more complicated than the viral reaction suggests.
For years, the phrase “U.S. biolabs in Ukraine” has been treated as either a Russian propaganda line or a legitimate biosecurity question, depending on who was speaking. The ODNI release does not prove that the United States was building biological weapons in Ukraine. It does not prove that COVID-19 came from these facilities. It does not prove that every overseas U.S.-supported lab was illegal or offensive in nature. What it does do is confirm that the U.S. government had a wider overseas biosurveillance and pathogen-research footprint than many officials were previously willing to discuss openly.
That distinction matters. Public health laboratories can be defensive, legal and useful. They can track outbreaks, improve diagnostics, help local governments identify dangerous pathogens and support global disease surveillance. But the same infrastructure can create dual-use risks: research that helps understand pathogens can also produce knowledge that makes pathogens more dangerous. Oversight, transparency, security and chain-of-command therefore become critical.
Gabbard’s release is powerful because it attacks the old credibility wall. If citizens were previously told that concern about U.S.-funded foreign biolabs was disinformation, and now the government says more than 120 such labs existed, many people will feel vindicated. That does not mean every conspiracy was true. It does mean official messaging was too dismissive, and that dismissal may now backfire.
The Ukraine angle is especially sensitive. Russia has repeatedly used allegations about U.S.-backed labs to justify its war narrative. The U.S. and Ukraine denied biological-weapons claims. The ODNI release gives Moscow propaganda material, but also exposes a real policy question: why fund sensitive pathogen work in conflict-prone regions without stronger public accountability?
The bigger issue is gain-of-function. Trump’s executive order is designed to stop federal money from supporting research that could enhance dangerous pathogens. Supporters say this is long overdue after the COVID era. Critics worry that a broad crackdown could weaken legitimate pandemic preparedness and push risky research into less transparent channels.
The correct headline is not “all conspiracies confirmed.” It is not “nothing to see here” either. The correct headline is that a major U.S. intelligence office is now acknowledging a global network of U.S.-funded biological laboratories and promising to identify what they contain and what research is being done.
That is a major transparency moment. It should be investigated seriously, not swallowed whole by panic or buried under partisan denial.